RESOLUTION

CSP29.R16

SITUATION UPDATE ON THE CHALLENGES OF SUPPLYING INACTIVATED POLIO VACCINE TO MAINTAIN ERADICATION OF THE DISEASE IN THE REGION OF THE AMERICAS

THE 29th PAN AMERICAN SANITARY CONFERENCE,

Having reviewed the Situation Update on the Challenges of Supplying Inactivated Polio Vaccine to Maintain Eradication of the Disease in the Region of the Americas (Document CSP29/16) on the historic achievements in the Region of the Americas with regard to polio eradication and the current challenges of supplying the inactivated polio vaccine (IPV);

Recognizing the valuable contributions made by the Pan American Health Organization’s Revolving Fund for Vaccine Procurement (the “Revolving Fund”) to guarantee timely and equitable access to polio vaccines for the Member States of the Pan American Health Organization (PAHO);

Considering the importance of the active participation of the Member States of PAHO in the Revolving Fund;

Reaffirming the principles, terms and conditions, and procedures of the Revolving Fund and its benefit for public health in the Region of the Americas (Resolution CD52.R5 [2013]);

Recognizing the importance of keeping the Region of the Americas polio-free and advancing toward the global eradication of this disease;

Aware of the special circumstances currently existing for implementation of the Polio Eradication and Endgame Strategic Plan 2013-2018, and the current situation of global demand and limited supply of IPV, as reported by the Director-General of WHO
in May 2017, as well as the importance of maintaining polio eradication in the Region of the Americas;

Considering, furthermore, that if the Revolving Fund managed to obtain additional doses of IPV, this would enable the Member States participating in the Revolving Fund to adequately plan the use of fractional doses of IPV (fIPV) administered intradermally in a two-dose series;

Recognizing that the Pan American Sanitary Bureau (the Bureau) requires the approval of the Member States of PAHO in order to conduct any negotiation that does not comply with the principles, terms and conditions, and procedures of the Revolving Fund,

RESOLVES:

1. To urge the Member States to:

a) continue to recognize the PAHO Revolving Fund as the strategic cooperation mechanism most suitable for providing access to vaccines such as IPV;

b) promote solidarity and Pan-Americanism through their participation in the Revolving Fund.

2. To request the Director to:

a) negotiate extraordinarily for the best possible price for procurement of IPV for the Region of the Americas and, if necessary, adjust the terms and conditions of the Revolving Fund for this occasion only, in order to address the special circumstances currently existing and provide the supply of IPV for the Region of the Americas;

b) maintain coordination with the Global Polio Eradication Initiative throughout this process in alignment with the Polio Eradication and Endgame Strategic Plan 2013-2018;

c) maintain dialogue with partners and global producers of IPV in order to accelerate and ensure the capacity to produce the necessary doses of IPV for the Region of the Americas;

d) continue to support the Member States of PAHO in preparation for the use of fIPV;

e) report in 2018 to the Executive Committee, through the Subcommittee on Program, Budget and Administration, on the situation of IPV supply in the Region of the Americas, and of extraordinary negotiations, if any are held, and the results achieved and progress made through the aforementioned dialogue.

(Eighth meeting, 28 September 2017)